RCM
CELU icon

Radcliffe Capital Management’s Celularity CELU Stock Holding History

Radcliffe Capital Management’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,500
Closed -$255K – 213
2020
Q2 		$255K Buy
+2,500
New +$248K 0.04% 140

Other funds holding CELU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Radcliffe Capital Management's CELU Position: Q3 2021 in Review

Radcliffe Capital Management sold out of Celularity (CELU) in Q3 2021, closing a stake of 8,729 shares — an estimated $889K sold.

Radcliffe Capital Management first reported a position in CELU in Q1 2020 and held it in 6 quarters. The position peaked at $1.85M in Q2 2020. 21 funds tracked by Wall St. Rank hold CELU as of Q3 2021.

  • Radcliffe Capital Management reported no remaining Celularity position as of Q3 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 8,729 Celularity shares in Q3 2021, an estimated $889K.
  • Radcliffe Capital Management first reported a position in Celularity in Q1 2020 and held it in 6 quarters.
  • Radcliffe Capital Management's Celularity position peaked at $1.85M in Q2 2020.
  • 21 funds tracked by Wall St. Rank held Celularity as of Q3 2021.

Based on Radcliffe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.